1. Home
  2. ACP vs ANNX Comparison

ACP vs ANNX Comparison

Compare ACP & ANNX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo abrdn Income Credit Strategies Fund

ACP

abrdn Income Credit Strategies Fund

HOLD

Current Price

$5.02

Market Cap

703.9M

Sector

Finance

ML Signal

HOLD

Logo Annexon Inc.

ANNX

Annexon Inc.

HOLD

Current Price

$5.01

Market Cap

730.4M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
ACP
ANNX
Founded
2010
2011
Country
United States
United States
Employees
N/A
N/A
Industry
Investment Managers
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
703.9M
730.4M
IPO Year
N/A
2020

Fundamental Metrics

Financial Performance
Metric
ACP
ANNX
Price
$5.02
$5.01
Analyst Decision
Strong Buy
Analyst Count
0
6
Target Price
N/A
$16.50
AVG Volume (30 Days)
497.7K
2.4M
Earning Date
01-01-0001
05-11-2026
Dividend Yield
17.79%
N/A
EPS Growth
N/A
42.94
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$4.92
$1.29
52 Week High
$5.99
$7.18

Technical Indicators

Market Signals
Indicator
ACP
ANNX
Relative Strength Index (RSI) 24.18 43.70
Support Level N/A $4.77
Resistance Level $5.69 $5.28
Average True Range (ATR) 0.07 0.37
MACD -0.02 -0.05
Stochastic Oscillator 1.36 5.48

Price Performance

Historical Comparison
ACP
ANNX

About ACP abrdn Income Credit Strategies Fund

abrdn Income Credit Strategies Fund is a diversified, closed-end management investment company. Its investment objective is to seek a high level of current income with a secondary objective of capital appreciation. It predominantly invests in debt and loan instruments of issues that operate in a variety of industries and geographic regions.

About ANNX Annexon Inc.

Annexon Inc is a clinical-stage biopharmaceutical company developing a pipeline of novel therapies for patients with classical complement-mediated disorders of the body, brain, and eye. Its pipeline is based on its platform technology addressing well-researched classical complement-mediated autoimmune and neurodegenerative disease processes, both of which are triggered by aberrant activation of C1q. Its pipeline of product candidates is designed to block the activity of C1q and the entire classical complement pathway in a broad set of complement-mediated diseases. Its product candidates are ANX005, for autoimmune & neurodegenerative disorders; ANX007, for neurodegenerative ophthalmic disorders; ANX1502 for Oral small molecule; and ANX009, for systemic autoimmune diseases.

Share on Social Networks: